Podcast appearances and mentions of Stewart J Tepper

To get the "Ultimate Guide To Migraine Freedom" go to mymigrainemiracle.com. There's a common perception that weather systems, or changes in barometric pressure, are a strong migraine trigger.  In this episode, learn the 3 key things to know when it comes to the weather and migraine connection.   LINKS MENTIONED:  MIGRAI-NEVERLAND, our premier resource for those who want to find their pill free path to migraine freedom (including the Beast Slayer Training Academy): mymigrainemiracle.com/endofmigraine Migraine Miracle Facebook group The book that started it all - The Migraine Miracle    Studies on the Migraine & Weather Connection:  Bolay, Hayrunnisa, and Alan Rapoport. 2011. “Does Low Atmospheric Pressure Independently Trigger Migraine?” Headache 51 (9): 1426–30. Elcik, Christopher, Christopher M. Fuhrmann, Andrew E. Mercer, and Robert E. Davis. 2017. “Relationship between Air Mass Type and Emergency Department Visits for Migraine Headache across the Triangle Region of North Carolina.” International Journal of Biometeorology 61 (12): 2245–54. Hoffmann, Jan, Hendra Lo, Lars Neeb, Peter Martus, and Uwe Reuter. 2011. “Weather Sensitivity in Migraineurs.” Journal of Neurology 258 (4): 596–602. Kimoto, Kazuhito, Saiko Aiba, Ryotaro Takashima, Keisuke Suzuki, Hidehiro Takekawa, Yuka Watanabe, Muneto Tatsumoto, and Koichi Hirata. 2011. “Influence of Barometric Pressure in Patients with Migraine Headache.” Internal Medicine 50 (18): 1923–28. Marmura, Michael J., and Pablo Bandres Hernandez. 2015. “High-Altitude Headache.” Current Pain and Headache Reports 19 (5): 483. Mukamal, Kenneth J., Gregory A. Wellenius, Helen H. Suh, and Murray A. Mittleman. 2009. “Weather and Air Pollution as Triggers of Severe Headaches.” Neurology 72 (10): 922–27. Prince, Patricia B., Alan M. Rapoport, Fred D. Sheftell, Stewart J. Tepper, and Marcelo E. Bigal. 2004. “The Effect of Weather on Headache.” Headache 44 (6): 596–602. Szyszkowicz, Mieczysław, Gilaad G. Kaplan, Eric Grafstein, and Brian H. Rowe. 2009. “Emergency Department Visits for Migraine and Headache: A Multi-City Study.” International Journal of Occupational Medicine and Environmental Health 22 (3): 235–42. Zebenholzer, Karin, Ernest Rudel, Sophie Frantal, Werner Brannath, Karin Schmidt, Ciçek Wöber-Bingöl, and Christian Wöber. 2011. “Migraine and Weather: A Prospective Diary-Based Analysis.” Cephalalgia: An International Journal of Headache 31 (4): 391–400.   DISCLAIMER This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this blog or materials linked from this blog is at the user's own risk. The content of this blog is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions.  

Medicine Grand Rounds August 23, 2019 Stewart J. Tepper, MD, FAHS Professor of Neurology Geisel School of Medicine at Dartmouth-Hitchcock Director, Dartmouth Headache Center Dartmouth-Hitchcock Medical Center

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Go online to PeerView.com/DCR860 to view the entire program with slides. Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem. In recent years a number of novel therapies for the acute treatment and prevention of migraine have been developed. These include centrally acting serotonin (5HT1F) agonists and therapies directed against the calcitonin gene-related peptide (CGRP) ligand and its receptor. In this activity, based on a recent live symposium held in Denver, Colorado, experts in neurology briefly review how migraine can be identified in clinical practice, discuss the latest data on emerging therapies for the acute treatment of migraine, assess current data on approved and emerging anti-CGRP monoclonal antibodies for migraine prevention, and highlight key considerations for using these therapies in clinical practice. Upon completion of this activity, participants will be able to: Apply established screening tools and criteria for migraine diagnosis in clinical practice, Identify data on the efficacy, safety, and tolerability of established and emerging therapeutics for the acute treatment of migraine, Cite updated evidence on available and emerging therapies for the prevention of migraine, Employ strategies to integrate emerging therapies for acute treatment and headache prevention into personalized management plans for patients with migraine if/when these agents are approved in the future.

Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?

Exploring the Latest Evidence on New and Emerging Therapies for Migraine Prevention: What Are the Potential Implications on Clinical Practice?